Author:
Bendell Johanna C.,Jones Suzanne F.,Hart Lowell,Spigel David R.,Lane Cassie M.,Earwood Chris,Infante Jeffrey R.,Barton John,Burris Howard A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference26 articles.
1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA: A Cancer Journal for Clinicians 62:10–29
2. Van Cutsem E, Peeters M, Siena S et al (2007) Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. J Clin Oncol 25:1658–1664
3. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev Cancer 2:489–501
4. Altomare I, Bendell JC, Bullock KE et al (2011) A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer. The Oncologist 16:1131–1137
5. Evans T, Lindsay CR, Chan E et al (2010) Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. ASCO Meeting Abstracts 28:2531
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献